Something Has to Give: The Current Unsustainable Approach to Safety Reporting Puts Trials and Patients at Risk

Safety reporting may be the most inefficient aspect of clinical trials today. It’s also among the most expensive, costing sponsors more than $700 million per year. Most are not receiving the best value for their investment, and some don’t even know how much they are spending. Automation has helped resolve some of the challenges, but it has created just as many. The system needs a complete overhaul. It can be done, but it requires the willing to invest in change.

About the Author

Steven Beales

An expert in the field of safety reporting technology, Mr. Beales has 25 years of experience in IT, and has spent over 16 years in the pharmaceutical industry. He joined WCG ePharmaSolutions in 2009 and led implementation of the company’s Clinical Trial Portal at Genentech across 100+ countries. In 2015, he led implementation of the Clinical Trial Safety Portal at a top 5 pharma organization, which included a data-driven rules engine configured with safety regulations from those countries, which saved this organization hundreds of millions of dollars. Over 50 million safety alerts have been distributed by these two portals via the cloud. Prior to joining WCG ePharmaSolutions, Mr. Beales was the Chief Software Architect at mdlogix, where he led the implementation of the CTMS systems for Johns Hopkins University, Washington University at St. Louis, the University of Pittsburgh, and the Interactive Autism Network for Autism Speaks.

Follow on Linkedin More Content by Steven Beales
Previous Post
Podcast: The Role of Expert Committees in Clinical Research with guest Jonathan Seltzer, MD, MBA, MA, FACC
Podcast: The Role of Expert Committees in Clinical Research with guest Jonathan Seltzer, MD, MBA, MA, FACC

Next Post
De-risking Clinical Trials Through Analytic Supported, On-Demand Medical Expertise From The World’s Leading Clinical Trial Experts
De-risking Clinical Trials Through Analytic Supported, On-Demand Medical Expertise From The World’s Leading Clinical Trial Experts

New Blog: "Ask the IRB Experts"

Visit Blog